2165. Assessing the Impact of Meropenem Exposure on Ceftolozane/tazobactam-resistance Development in Pseudomonas aeruginosa using in vitro Serial Passage

BACKGROUND: Patients infected with Pseudomonas aeruginosa with difficult-to-treat resistance are likely to receive meropenem (MEM) as an empiric therapy before escalation to broader agent such as ceftolozane/tazobactam (C/T) after antimicrobial susceptibility data are available. We assessed if pre-e...

Descripción completa

Detalles Bibliográficos
Autores principales: Fouad, Aliaa, Nicolau, Samantha, Tamma, Pranita, Simner, Patricia J, Nicolau, David P, Gill, Christian M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677790/
http://dx.doi.org/10.1093/ofid/ofad500.1788

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677790/
http://dx.doi.org/10.1093/ofid/ofad500.1788

Ejemplares similares